Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial

Sound Pharmaceuticals has concluded subject enrolment for its second Phase III clinical trial assessing SPI-1005 in adults with probable or definite Meniere’s disease in the US. The purpose of the trial is to collect additional safety data supporting chronic daily dosing of SPI-1005. Meniere’s disease is a complex inner ear disorder with low to mid frequency hearing loss, tinnitus, vertigo, and dizziness. Credit: NMK-Studio / Shutterstock.com. Sound Pharmaceuticals has concluded subject enrolment for its second Phase III clinical trial assessing SPI-1005 in adults with probable or definite Meniere’s disease in the US. The open label study enrolled 191 participants at…

Source: Clinical Trials Arena